Drugs / TCR-T therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05438667 | Jun 2023 → Jun 2026 | malignant pancreatic neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-T therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05438667 ↗ |
| Modality | Cell therapy | “autologous Tumor-T Cell Receptor (TCR) -Mediated T Cells therapy(TCR-T) therapy” NCT05438667 ↗ |
| Target | KRAS | “KRAS mutant antigen specific TCR-T cells” NCT05438667 ↗ |